Intrastromal voriconazole — Competitive Intelligence Brief

Intrastromal voriconazole (Intrastromal voriconazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triazole antifungal. Area: Ophthalmology / Infectious Disease.

phase 3 Triazole antifungal Lanosterol 14α-demethylase (CYP51) Ophthalmology / Infectious Disease Small molecule

Target snapshot

Intrastromal voriconazole (Intrastromal voriconazole) — University of California, San Francisco. Intrastromal voriconazole is an antifungal agent delivered directly into the corneal stroma to treat fungal keratitis by inhibiting fungal cell wall synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intrastromal voriconazole TARGET	Intrastromal voriconazole	University of California, San Francisco	phase 3	Triazole antifungal	Lanosterol 14α-demethylase (CYP51)
fast itraconazole tablet	fast itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
slow itraconazole tablet	slow itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 14α-demethylase (CYP51)
Diflucan (fluconazole)	Diflucan (fluconazole)	Pfizer	marketed	Triazole antifungal	Fungal cytochrome P450 14α-demethylase (CYP51)
anidulafungin and voriconazole	anidulafungin and voriconazole	Pfizer	marketed	Echinocandin and triazole antifungal combination	β-1,3-glucan synthase (anidulafungin); fungal CYP51/lanosterol 14α-demethylase (voriconazole)
medium itraconazole tablet	medium itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal CYP51 (lanosterol 14α-demethylase)
Vfend (voriconazole) tablet	Vfend (voriconazole) tablet	Seoul National University Hospital	marketed	Triazole antifungal	Cytochrome P450 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triazole antifungal class)

1. University of Maryland, Baltimore · 3 drugs in this class
2. Manjunath Prakash Pai · 2 drugs in this class
3. Pfizer · 2 drugs in this class
4. Janssen Pharmaceutical K.K. · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. Seoul National University Hospital · 1 drug in this class
8. University of California, San Francisco · 1 drug in this class
9. University of Minnesota · 1 drug in this class
10. Bayer · 1 drug in this class